K M Beavers1, D P Beavers, M C Serra, R G Bowden, R L Wilson. 1. Baylor University, Center for Exercise, Nutrition, and Preventive Health Research, Department of Health, Human Performance, and Recreation, Waco, TX 76798-7313, USA. Kristen_Beavers@baylor.edu
Abstract
BACKGROUND: Sarcopenia may be related to increases in reactive oxygen species formation and inflammation, both of which are associated with elevations in serum uric acid. OBJECTIVE: To test the hypothesis that a reduced skeletal muscle mass index, indicative of sarcopenia, is related to elevations in uric acid. DESIGN: Cross-sectional analysis of nationally representative data. SETTING: Third National Health and Nutrition Examination Survey, 1988-1994. PATIENTS: 7544 men and women 40 years of age and older who had uric acid, skeletal muscle mass, and select covariate information. MEASUREMENTS: Skeletal muscle mass assessment was based on a previously published equation including height, BIA-resistance, gender, and age. Absolute skeletal muscle mass was calculated for all study population individuals and compared against the sex-specific mean for younger adults. Serum uric acid data were gathered from the NHANES laboratory file. RESULTS: A logistic regression analysis revealed that elevations in serum uric acid are significantly related to sarcopenia status. For every unit (mg/dL) increase in uric acid, the odds ratio of manifesting a skeletal muscle mass index at least one standard deviation below the reference mean was 1.12. Participants in the highest grouping (> 8 mg/dL) of serum uric acid concentration had 2.0 times the odds of manifesting sarcopenia compared to the lowest grouping (< 6 mg/dL) (p < 0.01) after adjusting for the additional covariates. LIMITATIONS: This study design was limited in its cross-sectional nature. Potential selection, measurement, and recall bias may have occurred, and methodology used to classify sarcopenia status based on skeletal muscle mass index is not validated. CONCLUSION: This observation provides support for the theory that elevations in uric acid may lead to sarcopenia, although the proposed mechanism needs further experimental support.
BACKGROUND:Sarcopenia may be related to increases in reactive oxygen species formation and inflammation, both of which are associated with elevations in serum uric acid. OBJECTIVE: To test the hypothesis that a reduced skeletal muscle mass index, indicative of sarcopenia, is related to elevations in uric acid. DESIGN: Cross-sectional analysis of nationally representative data. SETTING: Third National Health and Nutrition Examination Survey, 1988-1994. PATIENTS: 7544 men and women 40 years of age and older who had uric acid, skeletal muscle mass, and select covariate information. MEASUREMENTS: Skeletal muscle mass assessment was based on a previously published equation including height, BIA-resistance, gender, and age. Absolute skeletal muscle mass was calculated for all study population individuals and compared against the sex-specific mean for younger adults. Serum uric acid data were gathered from the NHANES laboratory file. RESULTS: A logistic regression analysis revealed that elevations in serum uric acid are significantly related to sarcopenia status. For every unit (mg/dL) increase in uric acid, the odds ratio of manifesting a skeletal muscle mass index at least one standard deviation below the reference mean was 1.12. Participants in the highest grouping (> 8 mg/dL) of serum uric acid concentration had 2.0 times the odds of manifesting sarcopenia compared to the lowest grouping (< 6 mg/dL) (p < 0.01) after adjusting for the additional covariates. LIMITATIONS: This study design was limited in its cross-sectional nature. Potential selection, measurement, and recall bias may have occurred, and methodology used to classify sarcopenia status based on skeletal muscle mass index is not validated. CONCLUSION: This observation provides support for the theory that elevations in uric acid may lead to sarcopenia, although the proposed mechanism needs further experimental support.
Authors: Richard J Johnson; Mark S Segal; Titte Srinivas; Ahsan Ejaz; Wei Mu; Carlos Roncal; Laura G Sánchez-Lozada; Michael Gersch; Bernardo Rodriguez-Iturbe; Duk-Hee Kang; Jaime Herrera Acosta Journal: J Am Soc Nephrol Date: 2005-04-20 Impact factor: 10.121
Authors: Arnold B Alper; Wei Chen; Lillian Yau; Sathanur R Srinivasan; Gerald S Berenson; L Lee Hamm Journal: Hypertension Date: 2004-11-29 Impact factor: 10.190
Authors: Justine Beck; Luigi Ferrucci; Kai Sun; Jeremy Walston; Linda P Fried; Ravi Varadhan; Jack M Guralnik; Richard D Semba Journal: Biofactors Date: 2007 Impact factor: 6.113